News

May 2, 2023 - BioCentriq, Inc. and panCELLa, a Pluristyx Company, announced that they have signed a research agreement designed to evaluate the ability of panCELLa’s genetically-engineered, induced Pluripotent Stem Cell (iPSC)-derived, feeder cells to activate and positively impact the expansion rate, total yield and potency of manufactured NK cells. BioCentriq, a contract development and …

BioCentriq and panCELLa Execute Research Agreement to Study Stem Cell-derived Natural Killer Cell Expansion Technology Read More »

panCELLa granted patent in the United Kingdom for induced Allogeneic Cell Tolerance (iACT Stealth™) Technology January 12, 2023 – Toronto – Pluristyx and panCELLa today are excited to announce the granting of a patent used in their universal, off-the-shelf, induced pluripotent stem cells (iPSCs).  The Great Britain Patent Office on January 4, 2023 issued patent number …

Pluristyx and panCELLa Expand Intellectual Property Portfolio for Pluripotent Stem Cell Cloaking Technology  Read More »

August 2, 2022; Seattle Washington:  Blood Cell Storage Inc (BCSI), a medical device company whose products help assure the quality of platelet transfusions and help optimize the environment for embryo growth during in vitro fertilization procedures, today announce a grant award from the Advanced Regenerative Manufacturing Institute (armiusa.org) to create An Automated Cell Differentiation Monitoring …

Pluristyx and Blood Cell Storage, Inc. announces partnership to create An Automated Cell Differentiation Monitoring System for use in Tissue Engineered Medical Product (TEMP) Manufacturing.  Read More »

Accelerated Biosciences’ ethically sourced stem cells will be available for clinical product development in Q3 2022  SEATTLE, WA. – APRIL 26, 2022 – Pluristyx, Inc.   Pluristyx, Inc., an advanced therapy tools and services biotechnology company, and Accelerated Biosciences, a regenerative medicine innovator in the use of proprietary human trophoblast stem cells (hTSCs), today announced they …

Pluristyx and Accelerated Biosciences announce availability of clinical-grade immune-privileged human trophoblast stem cells (hTSCs)  Read More »

Improved access to induced pluripotent stem cells for allogeneic cell therapy applications SEATTLE, WA. – JANUARY 20, 2022 – Pluristyx, Inc. Pluristyx, Inc., an advanced therapy tools and services biotechnology company, panCELLa, a privately held biotechnology company, and Implant Therapeutics, a developer of genetically-engineered stem cells, today announced they have entered into a manufacturing and …

Pluristyx, panCELLa, and Implant Therapeutics announce a strategic alliance to manufacture and distribute genetically-modified, clinical-grade human-induced pluripotent stem cells  Read More »

TORONTO, Jan. 8, 2021 /CNW/ - panCELLa's intent to develop therapeutic products in the mesenchymal stem cell (MSC) and pancreatic islet space has recently led to the creation of Implant Therapeutics.    Implant Therapeutics, under the guidance of Dr. Mahendra Rao, is engineering iPSC-MSC cells containing panCELLa's FailSafe™ and induced Allogeneic Cell Tolerance (iACT Stealth Cell™) technologies.  These iPSC MSC cells …

Accelerating cell-based therapies by providing safe therapeutic MSC products  Read More »

TORONTO, April 7, 2020 /CNW/ - panCELLa is pleased to announce that it will receive advisory services and up to $400,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to help further research and development of its technology platforms for cell therapy.  Support from NRC IRAP will go toward the research and development of a two-step …

panCELLa receives research and development support for cell therapy  Read More »

TORONTO, April 3, 2020 /CNW/ - panCELLa is pleased to announce that it has extended an exclusive license to Astellas for its proprietary cell technology addressing long-term allogeneic cell tolerance without the need for immune suppression of patients. In addition to the license, the agreement includes a research collaboration plan to test and enhance the utility and …

panCELLa Extends Exclusive License to Astellas  Read More »

Hamburg, Germany, and Toronto, Canada, 02 April 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the innovative biotechnology company panCELLa Inc. announced today that the companies have entered into a licensing and investment agreement. Under the terms of the agreement, Evotec will receive a non-exclusive licence to access panCELLa’s proprietary iPS cell lines …

Evotec Expands its iPSC-Based Cell Therapy Platform EVOcells Through Licensing Agreement with panCELLa  Read More »